je.st
news
Tag: clinical
Good Documentation Practices for Clinical Trials Ensuring Air-Tight Results
2015-10-05 13:09:21| drugdiscoveryonline Home Page
Date: November 9, 2015 Time: 1pm - 2:30pm EST US Duration: 90 Minutes - Online Price: $299 - Includes Bonus Handouts!
Tags: good
results
documentation
practices
Stem cell clinical trials are multiplyingOct 3, 2015,
2015-10-04 02:25:06| Biotech - Topix.net
Lab work in September at the Sanford Consortium for Regenerative Medicine in La Jolla. / photo by Eduardo Contreras * U-T It's been a long wait for patients hoping for stem cell science to be turned into new treatments.
Tags: cell
clinical
stem
trials
Osmotica Announces FDA Acceptance Of Filing For Ontinua ER For Alleviation Of Spasticity Resulting From Multiple Sclerosis And Strong Advancement In The Clinical Program For Osmolex ER
2015-09-30 08:56:43| drugdiscoveryonline News Articles
Osmotica Pharmaceutical Corp. (privately held), a global specialty pharmaceutical corporation developing best-in-class therapeutics for the treatment of CNS diseases, announced recently that the New Drug Application (NDA) for OntinuaTM ER has been accepted for filing by the U.S. Food and Drug Administration (FDA)
Array BioPharma says clinical trials combining its cancer-fighting drugs show encouraging results
2015-09-29 07:51:26| Biotech - Topix.net
Robyn Hamor, associate scientist, works on an enzyme linked immunosorbent assay at Array BioPharma in Boulder, Colorado.
Tags: show
results
clinical
drugs
SYNDAX AND MERCK ANNOUNCE FIRST PATIENTS DOSED IN PHASE 1b/2 CLINICAL TRIAL OF ENTINOSTAT AND KEYTRUDA
2015-09-28 14:00:56| Merck.com - Product News
Dateline City: WALTHAM, Mass. and KENILWORTH, N.J. Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma WALTHAM, Mass. and KENILWORTH, N.J. Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndaxs entinostat in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma. Language: English read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] next »